Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2010, Vol. 32 ›› Issue (4): 403-406.doi: 10.3881/j.issn.1000-503X.2010.04.009

Previous Articles     Next Articles

Expressions of Human Epidermal Growth Factor Receptor 2 and Vascular Endothelial Growth Factor in Primary or Recurrent Metastatic Breast Cancers

WANG Zhi-kuan1,MENG Hai-yan2, HAN Chun1,YANG Jun-lan1   

  1. 1Department of Medical Oncology,PLA General Hospital,Beijing 100853,China;2Infirmary of Administrative Office of Yuan-Ming Yuan Imperial Garden,Beijing 100084,China
  • Received:2010-05-04 Online:2010-08-30 Published:2010-09-10
  • Contact: YANG Jun-lan E-mail:yangjunlan@medmail.com.cn

Abstract: Objective To investigate the expressions of human epidermal growth factor receptor 2(Her-2)and vascular endothelial growth factor(VEGF)in primary and recurrent metastatic breast cancers and explore their relationship. MethodsThe expressions of Her-2 and VEGF in 60 primary and recurrent metastatic breast cancers were detected using immunohistochamical methods. Their relationship was analyzed. ResultsThe positive rates of Her-2 and VEGF in the recurrent metastatic breast cancer were 40.00% and 53.33%, respectively, which were significantly higher than that in the primary breast cancer(18.33% and 31.67%)(P<0.05). The total diversify rates of Her-2 and VEGF were 28.33% and 35.00%, respectively. Her-2 and VEGF expressions were significantly correlated between the primary and the recurrent metastatic breast cancers(P<0.05). ConclusionsHer-2 and VEGF may play synergic roles in the occurrence and development of breast cancer. Over-expressions of Her-2 and VEGF predict poor prognosis.

Key words: breast cancer, primary focuses, recurrent metastatic focuses, human epidermal growth factor receptor 2, vascular endothelial growth factor

CLC Number: